In this paper, recently published in Annals of Internal Medicine, the authors describe 3 patients without previous neurological or autoimmune disorders who were diagnosed with myasthenia gravis after the onset of coronavirus disease 2019 (COVID-19). Symptoms of myasthenia gravis appeared within 5 to 7 days after fever onset in all 3 patients, and the time from presumed infection with SARS-CoV-2 to the beginning of myasthenia gravis symptoms was consistent with the time from infection to symptoms in other neurologic disorders triggered by infections. All patients improved after pyridostigmine bromide and prednisone treatment (patient 1); 1 cycle of intravenous immunoglobulin treatment (patient 2) and plasmapheresis sessions (patient 3).
Myasthenia Gravis Associated With SARS-CoV-2 Infection
You may also like
Effect of Convalescent Plasma on Organ Support–Free Days in Critically Ill Patients With COVID-19 A Randomized Clinical Trial
November 3, 2021
Neuropsychological profiles and cerebral glucose metabolism in neurocognitive Long COVID-syndrome
November 8, 2021
